<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890992</url>
  </required_header>
  <id_info>
    <org_study_id>DFI14223</org_study_id>
    <secondary_id>2015-003766-85</secondary_id>
    <secondary_id>U1111-1178-4764</secondary_id>
    <nct_id>NCT02890992</nct_id>
  </id_info>
  <brief_title>An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia</brief_title>
  <acronym>ODYSSEY KIDS</acronym>
  <official_title>An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels
      after 8 weeks of treatment in heterozygous familial hypercholesterolemia (heFH) patients age
      of 8 to 17 years, with LDL-C â‰¥130 mg/dL (3.37 mmol/L) on optimal stable daily dose of statin
      therapy +/- other lipid modifying therapies (LMTs) or a stable dose of non-statin LMTs in
      case of intolerance to statins for at least 4 weeks prior to the screening period.

      Secondary Objective:

        -  To evaluate the safety and tolerability of alirocumab.

        -  To evaluate the pharmacokinetics profile of alirocumab.

        -  To evaluate the effects of alirocumab on other lipid parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For Cohorts 1 to 3, a study duration of approximately 16-23 weeks (screening period: up to 6
      (+1) weeks, open-label dose finding treatment period: 8 weeks, follow up period: 6-8 weeks).

      For Cohort 4, a study duration of approximately 14-19 weeks (screening period up to 6 [+1]
      weeks, open-label dose finding treatment period: 12 weeks).

      Optional extension period: up to a maximum of 2 years for the first patients enrolled in
      Cohorts 1 to 3, but a maximum of approximately 5 months for the first patients enrolled in
      Cohort 4.

      For all patients who decline participation in the phase 3 study, their last alirocumab
      injection will be on December 2018.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 15, 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in calculated low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in calculated LDL-C</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a calculated LDL-C &lt;130 mg/dL (3.37 mmol/L)</measure>
    <time_frame>At Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a calculated LDL-C level &lt;110 mg/dL (2.84 mmol/L)</measure>
    <time_frame>At Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in calculated LDL-C (for Cohort 4)</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apolipoprotein B (Apo B)</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in non-high density lipoprotein cholesterol (non HDL-C)</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Total-C</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Lipoprotein (a) (Lp[a])</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in triglycerides (TG)</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in HDL-C</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apo A-1</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Apo B</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in non-HDL-C</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Total-C</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Lp(a)</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HDL-C</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in TG</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Apo A-1</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in ratio Apo B/Apo A-1</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypercholesterolaemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab Dose 1 will be administered subcutaneously (SC). Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 - Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab Dose 2 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab Dose 3 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental - Alirocumab Dose 4 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental - Alirocumab Dose 5 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental - Alirocumab Dose 6 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - Dose 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab Dose 7 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - Dose 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab Dose 8 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alirocumab SAR236553 (REGN727)</intervention_name>
    <description>Pharmaceutical form: solution Route of administration: subcutaneous injection</description>
    <arm_group_label>Cohort 1 - Dose 1</arm_group_label>
    <arm_group_label>Cohort 1 - Dose 2</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 3</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 4</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 5</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 6</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 7</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 8</arm_group_label>
    <other_name>Praluent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>statins</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>Cohort 1 - Dose 1</arm_group_label>
    <arm_group_label>Cohort 1 - Dose 2</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 3</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 4</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 5</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 6</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 7</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Cohort 1 - Dose 1</arm_group_label>
    <arm_group_label>Cohort 1 - Dose 2</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 3</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 4</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 5</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 6</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 7</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholestyramine</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Cohort 1 - Dose 1</arm_group_label>
    <arm_group_label>Cohort 1 - Dose 2</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 3</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 4</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 5</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 6</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 7</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>Cohort 1 - Dose 1</arm_group_label>
    <arm_group_label>Cohort 1 - Dose 2</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 3</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 4</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 5</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 6</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 7</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 fatty acids</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>Cohort 1 - Dose 1</arm_group_label>
    <arm_group_label>Cohort 1 - Dose 2</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 3</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 4</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 5</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 6</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 7</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotinic acid</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>Cohort 1 - Dose 1</arm_group_label>
    <arm_group_label>Cohort 1 - Dose 2</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 3</arm_group_label>
    <arm_group_label>Cohort 2 - Dose 4</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 5</arm_group_label>
    <arm_group_label>Cohort 3 - Dose 6</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 7</arm_group_label>
    <arm_group_label>Cohort 4 - Dose 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Children and adolescent male and female patients age of 8 to 17 years at the time of
             signed informed consent. For Russia only: Male and female patients aged â‰¥12 and â‰¤17
             years at the time of signed informed consent.

          -  Patients with diagnosis of heterozygous familial hypercholesterolemia (heFH) through
             genotyping or clinical criteria.

          -  Patients treated with optimal dose of statin +/- other LMT(s) or non-statin LMT(s) if
             statin intolerant at stable dose for at least 4 weeks prior to screening lipid
             sampling.

          -  Patients with calculated LDL-C greater than or equal to 130 mg/dL (â‰¥3.37 mmol/L) at
             the screening visit.

          -  Patients with body weight greater than or equal to 25kg.

          -  Patients age of 8 to 9 years to be at Tanner stage 1 and patients age of 10 to 17
             years to be at least at Tanner stage 2 in their development.

          -  A signed informed consent indicating parental permission with or without patient
             assent.

        Exclusion criteria:

          -  Patient with secondary hyperlipidemia.

          -  Diagnosis of homozygous familial hypercholesterolemia.

          -  Patient who has received lipid apheresis treatment within 2 months prior to the
             screening period, or has plans to receive it during the study.

          -  Known history of type 1 or type 2 diabetes mellitus.

          -  Known history of thyroid disease.

          -  Known history of hypertension.

          -  Fasting triglycerides &gt;350 mg/dL (3.95 mmol/L).

          -  Severe renal impairment (ie, estimated glomerular filtration rate [eGFR] &lt;30
             mL/min/1.73 mÂ².

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2 x upper limit of
             normal (ULN).

          -  Creatinine phosphokinase (CPK) &gt;3 x ULN.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400002</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400005</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240001</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030001</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030003</name>
      <address>
        <city>Praha 5 - Motol</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030002</name>
      <address>
        <city>Zlin</city>
        <zip>76275</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280001</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5780001</name>
      <address>
        <city>Oslo</city>
        <zip>0373</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430001</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430004</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7100001</name>
      <address>
        <city>Parow</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240004</name>
      <address>
        <city>A Coruna</city>
        <zip>15001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7520001</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Cholestyramine Resin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

